Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-12-12
2006-12-12
Chism, B. Dell (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S04400A
Reexamination Certificate
active
07148191
ABSTRACT:
The invention relates to a composition comprisinga T cell epitope or a mixture of T cell epitopesa polycationic peptide anda nucleic acid based on inosin and cytosin and its use as a vaccine.
REFERENCES:
patent: 3679654 (1972-07-01), Maes
patent: 3725545 (1973-04-01), Maes
patent: 6008334 (1999-12-01), Hanna
patent: 2003/0095979 (2003-05-01), Mattner et al.
patent: WO 97/30721 (1997-08-01), None
Harrington et al. 1979, Infection and Immunity, vol. 24, pp. 160-166.
Bloom et al., “Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma,”J. of Experimental Medicine, 185(3):453-459, 1997.
Buschle et al., “Chemically defined, cell-free cancer vaccines: use of tumor antigen-derived peptides or polyepitope proteins for vaccination,”Gene Therapy and Molecular Biology, 1:309-321, 1998.
Buschle et al., “Transloading of tumor antigen-derived peptides into antigen-presenting cells,”Proc. Natl. Acad. Sci., USA, 94:3256-3261, 1997.
Cavanaugh et al., “The activation of murine macrophages and natural killer cells by the partially thiolated double stranded RNA poly (I)-mercapto poly (C),”Research Communications in Molecular Pathology and Pharmacology, 91(2):131-147, 1996.
Cella et al., “Maturation, activation, and protection of dendritic cells induced by double-stranded RNA,”J. Exp. Med., 189(5):821-829, 1999.
Guggenheim and Baron, “Clinical studies of an interferon inducer, polyriboinosinic-polyribocytidylic acid [Poly (I) Poly (C)], in children,”Journal of Infectious Disease, 136:50-58, 1977.
Harrington et al., “Adjuvant effects of low doses of a nuclease-resistant derivative of polyniosinic acid polyctydiylic acid on antibody responses of monkeys to inactivated Venezuelan equine encephalomyelitis virus vaccine,”Infection and Immunity, 24:160-166, 1979.
Hoffman et al., “Phylogenetic perspective in innate immunity,”Science, 284:1313-1317, 1999.
Lethe et al., “Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide,”Eur. J. Immunol., 22:2283-2288, 1992.
Manetti et al., “Polyinosinic acid: polycytidylic acid promotes T helper type 1-specific immune response by stimulating macrophage production of interferon-α and interleukin-12,”Eur J. Immunol., 25:2656-2660, 1995.
Salazar et al., “Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study,”Neurosurgery, 38:1096-1104, 1996.
Schmidt et al., “Cell-free tumor antigen peptide-based cancer vaccines,”Proc. Natl. Acad. Sci., USA, 94:3262-3267, 1997.
Simmler et al., “Clinical trial of Poly I-Poly C as an immunity adjuvant and an immunorestoration agent,”Europ. J. Cancer, 13:463-467, 1997.
Singh and O'Hagan, “Advances in vaccine adjuvants,”Nat. Biotechnology, 17:1075-1081, 1999.
Verdijk et al., “Polyriboinosinic polyribocytidylic acid (Poly(I:C)) incuces stable maturation of functionally active human dendritic cells,”J. of Immunology, 163:57-61, 1999.
Buschle Michael
Egyed Alena
Lingnau Karen
Mattner Frank
Schmidt Walter
Chism B. Dell
Fulbright & Jaworski
Intercell AG
LandOfFree
Antigenic composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antigenic composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antigenic composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3704353